Preliminary study on proteomics of gastric carcinoma and its clinical significance

Table 1 Samples of control and gastric cancer staged by TNM classification

	Training group	Test group	Total
Gastric cancer	30	40	70
Stage I	6	6
Stage II	4	5
Stage III	12	16
Stage IV	8	13
Control	30	30	60
Total	60	70	130

Table 2 Mass peaks found in the model group

M/Z	P	Mean-cancer	Mean-control
7 567	3.7E-09	9.92	2.14
15 117	1.024E-07	10.14	1.69
15 326	2.675E-07	2.57	0.6
15 847	2.86434E-05	7.08	2.32
5 252	7.42542E-05	1.59	4.24
2 675	0.000603611	1.16	2.29
5 546	0.000879454	2.09	3.97
7 934	0.001268535	8.04	3.25
4 524	0.001335592	2.63	1.66
5 340	0.001335592	14.9	27.46
8 052	0.001637839	3.8	1.86
4 177	0.002210593	2.8	6.73
3 995	0.005201923	1.35	1.97
6 982	0.007451088	2.78	1.78
4 714	0.008874709	3.1	2.08
3 245	0.009673852	1.49	2.26

Table 3 Statistical summary of the model (by BPS)

Group	Sensitivity (%)	Specificity (%)	Accuracy (%)
Training	96.7	96.7	96.7
Test	90	86.7	88.6

Table 4 Status of the miss-judged test samples

Sex	Age (yr)	Differentiation of tumorgy	TNM	Stage
1 Female	32	Poor	T4N1M1	IV
2 Male		58	Poor, partially with signet
		ring cell	T3N2M0	III
3 Female	63	Poor	T4N2M1	IV
4 Female	50	Poor, partially with signet
		ring cell	T4N1M0	III